References
- Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102.
- Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American diabetes Association (ADA) and the European Association for the study of diabetes (EASD). Diabetologia. 2022;65(12):1925–1966. doi: 10.1007/s00125-022-05787-2
- Rizzo M, Nauck MA, Mantzoros CS. Incretin-based therapies in 2021 - Current status and perspectives for the future. Metabolism. 2021;122:154843. doi: 10.1016/j.metabol.2021.154843
- Monami M, Nreu B, Scatena A, et al. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. Diab Obes Metab. 2017;19(9):1233–1241. doi: 10.1111/dom.12926
- He L, Wang J, Ping F, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022;182(5):513–519. doi: 10.1001/jamainternmed.2022.0338
- Rizvi AA, Rizzo M. The emerging role of dual GLP-1 and GIP receptor agonists in glycemic Management and cardiovascular risk reduction. Diabetes Metab Syndr Obes. 2022;15:1023–1030. doi: 10.2147/DMSO.S351982
- Heise T, Mari A, DeVries JH, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomized, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022;10(6):418–429. doi: 10.1016/S2213-8587(22)00085-7
- Thomas MK, Nikooienejad A, Bray R, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021;106(2):388–396. doi: 10.1210/clinem/dgaa863
- Urva S, Coskun T, Loghin C, et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diab Obes Metab. 2020;22(10):1886–1891. doi: 10.1111/dom.14110
- Muzurović EM, Volčanšek Š, Tomšić KZ, et al. Glucagon-like peptide-1 receptor agonists and dual glucose-dependent insulinotropic polypeptide/Glucagon-like peptide-1 receptor agonists in the treatment of obesity/metabolic syndrome, prediabetes/diabetes and non-alcoholic fatty liver disease-current evidence. J Cardiovasc Pharmacol Ther. 2022;27:10742484221146371. doi: 10.1177/10742484221146371
- Karagiannis T, Avgerinos I, Liakos A, et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022;65(8):1251–1261. doi: 10.1007/s00125-022-05715-4
- Rizvi AA, Linhart A, Vrablik M, et al. Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections. Expert Opin Drug Saf. 2022;21(3):291–293. doi: 10.1080/14740338.2022.2043848
- Patoulias D, Fragakis N, Rizzo M. The therapeutic role of SGLT-2 inhibitors in acute heart failure: from pathophysiologic mechanisms to clinical evidence with pooled analysis of relevant studies across safety and efficacy endpoints of interest. Life. 2022;12(12):2062. doi: 10.3390/life12122062
- Marzolla V, Infante M, Armani A, et al. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective. Expert Opin Drug Saf. 2022;21(9):1161–1170. doi: 10.1080/14740338.2022.2130889
- Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591–598. doi: 10.1038/s41591-022-01707-4